| [November 12, 2014] |
 |
Biothera's Imprime PGG Named to Top 10 List of Most Interesting Oncology Projects to Watch
EAGAN, Minn. --(Business Wire)--
Biothera has been chosen by Informa (News - Alert) and Kantar Health as one of the 2014
Top 10 Most Interesting Oncology Projects to Watch for its cancer
immunotherapy candidate Imprime PGG®.
Products selected as one of the Most
Interesting Oncology Projects to Watch have met rigorous
criteria, including unmet medical need, market potential, diversity of
indications, strong science, partnering opportunities, and potential for
new opportunities beyond initial indications.
Imprime PGG is a novel innate immune cell modulator that primes
neutrophils, monocytes and macrophages through a complement receptor 3
(CR3)-dependent mechanism to exert anti-tumor activity against tumor
cells that have been opsonized with complement following targeting with
anti-tumor antibodies.
"Selected products have been screened using a strict set of judging
criteria for the Top 10 award and represent what Informa and Kantar
Health consider among the most attractive opportunities the industry has
to offer," said Bill Bagwell, General Manager, Oncology, Kantar Health.
"As an industry leader in oncology strategic research and consulting, it
is exciting to give these companies exposure to potential investors,
partners and acquirers."
"We are honored to be recognized for our ability to make a significant
contribution to the treatment of cancer by engaging and directing the
immune systm," said Dan Conners, President of Biothera's Pharmaceutical
Group. "Imprime PGG's novel mechanism of action has the potential to
treat a wide range of cancers."
Biothera to Present at Informa's Therapeutic Area Partnerships Meeting
Steve
Smith, Biothera's Senior Vice President of Commercial Development for
its Pharmaceutical Group, will present at Informa's Therapeutic Area
Partnerships meeting on November 19-21 at the Hyatt Regency in Boston.
Mr. Smith's presentation on Imprime PGG will occur at 1:10 PM EST on
November 20, within Track 3 (Oncology).
About Biothera
Biothera, a privately held U.S. biotechnology
company, is developing Imprime PGG, a late clinical stage biologic that
modulates the immune response to cancer. Data from the most recent
randomized phase 2 study of Imprime PGG in first line non-squamous NSCLC
was featured as a late-breaking
abstract in the Immunotherapy of Cancer session at ESMO 2014. In
this study, which evaluated the addition of Imprime PGG to bevacizumab
and carboplatin/paclitaxel versus bevacizumab and chemotherapy alone,
objective response rate was 60.4% versus 43.5%, duration of response was
10.3 months versus 5.6 months and median overall survival was 16.1
months versus 11.6 months. Similarly encouraging data
have been observed in both squamous and non-squamous subjects in a
second randomized Phase 2 study in 1st line NSCLC in combination with
cetuximab and in studies in high-risk chronic lymphocytic leukemia and
metastatic colorectal cancer. Imprime PGG directly modulates the key
effector cells of the innate immune system, neutrophils and
monocytes/macrophage, enabling them to recognize and kill
antibody-targeted cancer cells. In addition, on-going research points to
a secondary, bystander effect of Imprime PGG on both innate and adaptive
immune cell types known to exist in the tumor microenvironment,
including T-cells, dendritic cells, M-2 macrophages and myeloid derived
suppressor cells. Imprime PGG is being evaluated in a phase 3 study in
late stage metastatic colorectal cancer and planning is underway for an
approvable study in NSCLC.
More information is available at www.biothera.com/pharma
or follow us on Twitter.
[ Back To TMCnet.com's Homepage ]
|
